FLT3 and acute myeloid leukemia: Clinically, patients with Fms-related tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutation are the largest subgroup of AML, which is associated with an increased relapse risk and decreased disease-free survival [24].